Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Meta-analysis of 60 phase 2, 3,or 4 RCTs of treatments licensed by FDA and EMA for adults with moderate to severe psoriasis suggests brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with highest PASI response rates in both short-term and long-term therapy
Source:
JAMA Dermatology
SPS commentary:
An accompanying editorial discusses the strengths and weaknesses of network meta-analyses. It notes that the raw rankings of efficacy as determined by this current study and other recently published network meta-analyses offer a valuable starting point from which to initiate discussions with patients and improve shared decision making related to choosing the most appropriate psoriasis treatment.